Table 2.
Results of meta-regression analyses.
| Cohorts | Covariate | N studies | RR | p- | R2 |
|---|---|---|---|---|---|
| (95% CI) | value | (%) | |||
| Only vaccine studies | % male (per 5%-point increase in prop male) | 6 | 1.15 (0.96 to 1.37) | 0.13 | 40 |
| Age (per 5-year increase) | 5 | 0.74 (0.61 to 0.89) | 0.002 | 100 | |
| Follow-up (per 7-d increase from vaccination) | 8 | 0.97 (0.71 to 1.13) | 0.87 | 0.0 | |
| mRNA vaccines vs. other | 8 | 1.70 (0.67 to 4.31) | 0.26 | 0.0 | |
| Americas | 7 | 1.45 (0.56 to 3.75) | 0.44 | 6.0 | |
| Vaccines and infection studies | % male (per 5%-point increase in prop male) | 9 | 1.38 (1.14 to 1.68) | 0.0009 | 89 |
| Age (per 5-y increase) | 8 | 0.98 (0.88 to 1.10) | 0.76 | 0 | |
| Follow-up (per 7-d increase from vaccination) | 10 | 1.11 (0.45 to 2.74) | 0.82 | 6 | |
| Americas vs. other WHO regions | 11 | 2.94 (1.17 to 7.44) | 0.02 | 82 |
Bold values are statistically significant. R2: Coefficient of determination represents the amount of variation in the risk of myocarditis explained by the covariate in the meta-regression model.